SCHEMBL20595902

SCHEMBL20595902

O=c1n(Cc2nc3nc(F)ccc3[nH]2)cc(Cc2ccc(Cl)cc2Cl)n1CC(F)F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MARS2 Q96GW9 9/20 1.00
CDC7 O00311 1/20 0.32
ATM Q13315 1/20 0.31
TSHR P16473 1/20 0.31
PDE9A O76083 1/20 0.30
JAK2 O60674 1/20 0.30
ROCK2 O75116 1/20 0.30
CHEK2 O96017 1/20 0.30
PRKACA P17612 1/20 0.30
GSK3A P49840 1/20 0.30
RPS6KA3 P51812 1/20 0.30
PRKCD Q05655 1/20 0.30
PRKAA1 Q13131 1/20 0.30
PAK1 Q13153 1/20 0.30
ROCK1 Q13464 1/20 0.30
DYRK1A Q13627 1/20 0.30
CDC42BPA Q5VT25 1/20 0.30
AURKB Q96GD4 1/20 0.30
PRKD2 Q9BZL6 1/20 0.30
IRAK4 Q9NWZ3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20596018 0.93 MARS2 (1.00) MARS2CDC7ATMTSHRJAK2
SCHEMBL20596217 0.90 MARS2 (1.00) MARS2CDC7TSHR
SCHEMBL20595911 0.89 MARS2 (0.85) MARS2
SCHEMBL20596001 0.89 MARS2 (1.00) MARS2TSHR
SCHEMBL20596022 0.89 MARS2 (0.81) MARS2CDC7ATMTSHRPRMT5
SCHEMBL20596104 0.89 MARS2 (0.84) MARS2ATMTSHR
SCHEMBL20595995 0.87 MARS2 (0.76) MARS2PDE9A
SCHEMBL20596172 0.86 MARS2 (0.83) MARS2TSHR
SCHEMBL23419640 0.86 MARS2 (0.75) MARS2CDC7ATMTSHR
SCHEMBL20596320 0.86 MARS2 (0.77) MARS2PDE9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MARS2 12/4885CDC7 2772/4885ATM 2840/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR MARS2 5/4885CDC7 2726/4885ATM 2620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.